Search

Distributing medicine globally with pharmaceutical logistics

From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Equestrian sports horse health awareness Alex Hua Tian

Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.

Digital innovation: Our digital pipeline is only growing

BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.

Shared science for the best cat diabetes management

Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.

We are Global Top Employer 2024

Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.

SENVELGO Best New Product Companion Animals award

SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award

Mareks Disease Poultry Chicken

Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs

We’re looking for SAP developers to join our Global IT Department

Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!

Fabio Paganini fostering inclusion & agility in AH

How employees are contributing to an inclusive culture at Boehringer Ingelheim.

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

Second cancer immunotherapy partnership with 3T Bio

Accelerating new cancer medicines in partnership with CBmed

Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients

Major investment for respiratory diseases completed

105 million euros invested into expansion of production facilities in Ingelheim and Dortmund

Partnering-with-google-in-quantum-computing

New cooperation with Google explores the potentials of quantum computing for pharma R&D.

Nerandomilast (BI 1015550): PDE4B inhibitor